Simcha Therapeutics signs license agreement with Janssen for DR-18
The deal, facilitated by Johnson & Johnson Innovation, will enable Janssen to develop cell therapies that are armed with DR-18 of Simcha. Janssen will be responsible for the
Ferring Pharmaceuticals and SK pharmteco have entered into an agreement to increase commercial manufacturing capacity for Ferring’s ADSTILADRIN (nadofaragene firadenovec-vncg), ensuring a long-term supply of the non-replicating adenoviral vector-based gene therapy.
This partnership covers drug-linker technology and CRDMO services right from discovery to commercialisation. WuXi XDC CEO Dr. Jimmy Li said, “IntoCell’s unique drug-linker technologies and our leading, open-access